Lidocaïne Hydrochloride Renaudin

Lidocaine, the active ingredient in Lidocaïne Hydrochloride Renaudin, is a local anesthetic (amide type) presented as a sterile intravenous solution for intravenous use. It provides local anesthesia for minor surgical or diagnostic procedures and is also employed in the management of ventricular arrhythmias.

GNH USA supplies Lidocaïne Hydrochloride Renaudin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable logistics for global distribution.

Lidocaine Hydrochloride is used in clinical settings to provide local anesthesia and to treat certain cardiac rhythm disturbances. - Minor surgical procedures: Provides rapid onset local anesthesia to facilitate painless incision and excision. - Dental procedures: Enables effective numbing of oral tissues for extractions, restorations and other dental work. - Ventricular arrhythmias: Suppresses ectopic ventricular activity to stabilize cardiac rhythm during acute episodes.

Lidocaine may be associated with a range of adverse reactions, varying from mild and transient to severe and life‑threatening.

Common Side Effects: - Dizziness: Transient sensation of light‑headedness or imbalance. - Tinnitus: Ringing or buzzing in the ears. - Metallic taste: Unpleasant metallic sensation in the mouth. - Perioral numbness: Tingling or loss of sensation around the lips.

Serious or Rare Side Effects: - Seizures: Generalized convulsions due to central nervous system toxicity. - Cardiac arrest: Sudden loss of cardiac output, potentially fatal. - Severe allergic reaction: Anaphylaxis presenting with rash, bronchospasm, or hypotension.

When using lidocaine, clinicians should observe several safety considerations to minimize risk. - Allergy assessment: Verify no known hypersensitivity to amide‑type local anesthetics. - Cardiac conduction disorders: Use cautiously in patients with pre‑existing heart block or severe bradycardia. - Hepatic impairment: Adjust dosing or monitor plasma levels in patients with significant liver dysfunction. - Pregnancy and lactation: Safety category is unknown; weigh potential benefits against risks before use. - Concomitant CNS depressants: Monitor for enhanced central effects when combined with other sedatives or anticonvulsants. - Store at room temperature: Keep in original container, protect from moisture and light, and do not freeze.

Lidocaine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): Combined use may precipitate severe cardiac toxicity. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): Can increase lidocaine plasma concentrations, raising risk of toxicity. - Other sodium channel blockers (e.g., mexiletine): Additive effects may lead to profound conduction disturbances.

Moderate Interactions (Monitor Closely): - Beta‑blockers (e.g., propranolol): May enhance bradycardic effects. - Calcium channel blockers (e.g., verapamil): Potential for additive negative inotropic impact. - Other local anesthetics: Concurrent administration can increase total systemic exposure.